Quality of life in patients with primary biliary cirrhosis
- PMID: 15368455
- DOI: 10.1002/hep.20276
Quality of life in patients with primary biliary cirrhosis
Abstract
The impact of primary biliary cirrhosis (PBC) on health-related quality of life (HRQOL) is poorly documented. We assessed quality of life in a group of 276 unselected patients with PBC using the Nottingham Health Profile (NHP). This is a generic scale that assesses six major areas commonly associated with HRQOL. Data were compared with those of a sex- and age-matched control group. The associations between NHP scores and the severity of PBC were tested. Patients (86% women) had a median age of 62 years (range 33-87). Most patients were treated with UDCA. PBC patients showed a strong statistically significant difference in energy compared to controls (respectively, 40.6 vs. 22.9, P < .0001) and had worse scores for emotional reactions (22.2 vs. 16.1, P < .005). No other differences were observed. No associations of the dimension subscores were found with biochemical liver tests, histological stages, or duration of the disease. Among the signs or symptoms, fatigue was the finding most often associated with the dimension subscores. In conclusion, patients with PBC feel that their overall quality of life is worse than that of the control population. This difference is mainly due to the decrease in the subscores of energy and emotional reactions, both associated with fatigue. These effects must be taken into account by clinicians when treating these patients, as they constitute the clinical outcomes that have the most impact on patients' lifestyle and adherence to treatment.
Copyright 2004 American Association for the Study of Liver Diseases
Similar articles
-
Impact of fatigue on the quality of life of patients with primary biliary cirrhosis.Am J Gastroenterol. 2000 Mar;95(3):760-7. doi: 10.1111/j.1572-0241.2000.01857.x. Am J Gastroenterol. 2000. PMID: 10710071
-
Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.Aliment Pharmacol Ther. 2006 Sep 1;24(5):813-20. doi: 10.1111/j.1365-2036.2006.03048.x. Aliment Pharmacol Ther. 2006. PMID: 16918885
-
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.Liver Transpl. 2007 Sep;13(9):1236-45. doi: 10.1002/lt.21124. Liver Transpl. 2007. PMID: 17763401
-
The natural history of PBC: has it changed?Semin Liver Dis. 2005 Aug;25(3):321-6. doi: 10.1055/s-2005-916323. Semin Liver Dis. 2005. PMID: 16143947 Review.
-
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.Clin Liver Dis. 2008 May;12(2):425-43; x-xi. doi: 10.1016/j.cld.2008.02.008. Clin Liver Dis. 2008. PMID: 18456189 Review.
Cited by
-
Reduced brain content of arachidonic acid and docosahexaenoic acid is related to the severity of liver fibrosis.Dig Dis Sci. 2010 Oct;55(10):2831-7. doi: 10.1007/s10620-009-1120-x. Epub 2010 Jan 26. Dig Dis Sci. 2010. PMID: 20101460
-
Clinical features and management of primary sclerosing cholangitis.World J Gastroenterol. 2008 Jun 7;14(21):3338-49. doi: 10.3748/wjg.14.3338. World J Gastroenterol. 2008. PMID: 18528931 Free PMC article. Review.
-
Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.Liver Transpl. 2005 Oct;11(10):1252-7. doi: 10.1002/lt.20511. Liver Transpl. 2005. PMID: 16184542 Free PMC article.
-
Risk Stratification in Primary Biliary Cholangitis.J Clin Med. 2023 Sep 1;12(17):5713. doi: 10.3390/jcm12175713. J Clin Med. 2023. PMID: 37685780 Free PMC article. Review.
-
Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison.J Transl Autoimmun. 2021 Jan 6;4:100081. doi: 10.1016/j.jtauto.2021.100081. eCollection 2021. J Transl Autoimmun. 2021. PMID: 33554101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources